DDE Labs works with emerging technology companies to translate research programs from the lab to clinical development.

Some of our partners and collaborators are shown below.

Sensulin logo

Sensulin, LLC, San Diego, California
Sensulin is developing a glucose-responsive insulin to support prandial and basal requirements of Type 1 and Type 2 diabetics with a single daily injection.

DDE Labs runs the R&D program including all of the chemistry, formulation, analytical, in vivo efficacy models, toxicity testing, and bioanalytical for Sensulin.

Abvance Therapeutics, Ltc, Nashville, Tennessee
Abvance Therapeutics is a pharmaceutical startup company specializing in metabolic hormones.

DDE Labs is developing proprietary co-formulations for Abvance.

DIAVACS, Inc., La Jolla, California
DIAVACS is a San Diego-based clinical stage biotechnology company developing products to reverse the onset of autoimmune disease.

DDE Labs ran the product development effort for the nanoparticle vaccine program.

Veru, Inc., Miami, Florida
Veru Inc. is an oncology and urology biopharmaceutical company developing and commercializing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals.

DDE Labs developed VERU-100, the GnRH antagonist long-acting formulation with 3 months of exposure currently in clinical development.